Other neurodegenerative disorders Emerging clinical data suggest the safety and some potential benefits of GLP-1 medicines in patients with multiple sclerosis (MS), although the data are limited
Survodutide achieved comparable glycemic efficacy to semaglutide at low doses, while higher doses surpassed semaglutide in weight loss
This dose is sub-therapeutic meaning it will not produce measurable weight loss and exists solely to allow your body to adapt to the medication and minimise gastrointestinal side effects
Probiotics Supporting Gut Health and Digestive Comfort Why it matters: GLP-1 medications alter gut motility, which can disrupt the microbiome and trigger symptoms like bloating, diarrhea, and digestive discomfort, particularly in the early weeks of treatment
Wegovy og Ozempic er GLP-1 agonister Fedmemidlet Wegovy er et handelsnavn for lgemidlet semaglutid, der er en syntetisk udgave af et hormon, der naturligt findes i kroppen, kendt som GLP-1 (glucagon-like peptide-1)